PMID- 21248270
OWN - NLM
STAT- MEDLINE
DCOM- 20110307
LR  - 20211020
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 186
IP  - 3
DP  - 2011 Feb 1
TI  - Recent developments in cancer vaccines.
PG  - 1325-31
LID - 10.4049/jimmunol.0902539 [doi]
AB  - The adoptive transfer of cancer Ag-specific effector T cells in patients can 
      result in tumor rejection, thereby illustrating the immune system potential for 
      cancer therapy. Ideally, one would like to directly induce efficient 
      tumor-specific effector and memory T cells through vaccination. Therapeutic 
      vaccines have two objectives: priming Ag-specific T cells and reprogramming 
      memory T cells (i.e., a transformation from one type of immunity to another, for 
      example, regulatory to cytotoxic). Recent successful phase III clinical trials 
      showing benefit to the patients revived cancer vaccines. Dendritic cells (DCs) 
      are essential in generation of immune responses, and as such represent targets 
      and vectors for vaccination. We have learned that different DC subsets elicit 
      different T cells. Similarly, different activation methods result in DCs able to 
      elicit distinct T cells. We contend that a careful manipulation of activated DCs 
      will allow cancer immunotherapists to produce the next generation of highly 
      efficient cancer vaccines.
FAU - Palucka, Karolina
AU  - Palucka K
AD  - Baylor Institute for Immunology Research, Baylor University Medical Center, 
      Dallas, TX 75204, USA.
FAU - Ueno, Hideki
AU  - Ueno H
FAU - Banchereau, Jacques
AU  - Banchereau J
LA  - eng
GR  - U19 AI057234-06S1/AI/NIAID NIH HHS/United States
GR  - R01 CA078846-07/CA/NCI NIH HHS/United States
GR  - R01 CA078846-08/CA/NCI NIH HHS/United States
GR  - U19 AI057234-05/AI/NIAID NIH HHS/United States
GR  - R01 CA078846-01A1/CA/NCI NIH HHS/United States
GR  - R01 CA078846-02/CA/NCI NIH HHS/United States
GR  - U19 AI057234-07/AI/NIAID NIH HHS/United States
GR  - U19 AI057234-06S3/AI/NIAID NIH HHS/United States
GR  - P01 CA084512-07/CA/NCI NIH HHS/United States
GR  - U19 AI057234-04/AI/NIAID NIH HHS/United States
GR  - R01 CA140602/CA/NCI NIH HHS/United States
GR  - R01 CA089440-04/CA/NCI NIH HHS/United States
GR  - R01 CA089440-02/CA/NCI NIH HHS/United States
GR  - U19 AI057234-02/AI/NIAID NIH HHS/United States
GR  - R01 CA089440-01A1/CA/NCI NIH HHS/United States
GR  - R01 CA078846-04/CA/NCI NIH HHS/United States
GR  - U19 AI057234-01/AI/NIAID NIH HHS/United States
GR  - P01 CA084512-07S1/CA/NCI NIH HHS/United States
GR  - U19 AI057234-07S1/AI/NIAID NIH HHS/United States
GR  - P01 CA084512-05A2/CA/NCI NIH HHS/United States
GR  - R01 CA078846-05/CA/NCI NIH HHS/United States
GR  - P01 CA084512-07S2/CA/NCI NIH HHS/United States
GR  - P01 CA084512/CA/NCI NIH HHS/United States
GR  - U19 AI057234-08/AI/NIAID NIH HHS/United States
GR  - R01 CA078846-10/CA/NCI NIH HHS/United States
GR  - P01 CA084512-06/CA/NCI NIH HHS/United States
GR  - R01 CA078846-06/CA/NCI NIH HHS/United States
GR  - U19 AI057234-06/AI/NIAID NIH HHS/United States
GR  - R01 CA078846-09/CA/NCI NIH HHS/United States
GR  - U19 AI057234-05S1/AI/NIAID NIH HHS/United States
GR  - CA078846/CA/NCI NIH HHS/United States
GR  - U19 AI057234/AI/NIAID NIH HHS/United States
GR  - R01 CA089440/CA/NCI NIH HHS/United States
GR  - U19 AI057234-06S2/AI/NIAID NIH HHS/United States
GR  - U19 AIO57234/PHS HHS/United States
GR  - R01 CA089440-03/CA/NCI NIH HHS/United States
GR  - U19 AI057234-03/AI/NIAID NIH HHS/United States
GR  - R01 CA078846-03/CA/NCI NIH HHS/United States
GR  - R01 CA078846/CA/NCI NIH HHS/United States
GR  - P01 CA084514/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/*administration & dosage/*immunology/therapeutic use
MH  - Cancer Vaccines/*administration & dosage/*immunology/therapeutic use
MH  - Dendritic Cells/immunology/metabolism
MH  - Drug Delivery Systems/methods/trends
MH  - Humans
MH  - Immunologic Memory
MH  - Immunotherapy, Adoptive/methods/trends
MH  - Randomized Controlled Trials as Topic
MH  - T-Lymphocyte Subsets/immunology/metabolism
PMC - PMC3060768
MID - NIHMS277697
EDAT- 2011/01/21 06:00
MHDA- 2011/03/08 06:00
PMCR- 2012/02/01
CRDT- 2011/01/21 06:00
PHST- 2011/01/21 06:00 [entrez]
PHST- 2011/01/21 06:00 [pubmed]
PHST- 2011/03/08 06:00 [medline]
PHST- 2012/02/01 00:00 [pmc-release]
AID - 186/3/1325 [pii]
AID - 10.4049/jimmunol.0902539 [doi]
PST - ppublish
SO  - J Immunol. 2011 Feb 1;186(3):1325-31. doi: 10.4049/jimmunol.0902539.